Rapid Novor has published a study that highlights the power of
combining de novo antibody protein sequencing with conventional
proteomics to uncover functional and neutralizing antibodies in
human plasma following SARS-CoV-2 vaccination. This innovative
approach identified novel antibodies that were not detected through
traditional B-cell sequencing, showcasing the potential for
discovering unique antibodies from previously untapped aspects of
the immune response.
KITCHENER, ON , Oct. 10,
2024 /PRNewswire-PRWeb/ -- Rapid Novor Inc., the
world's leader in mass spectrometry (MS)-based antibody sequencing,
published a peer-reviewed research article where REpAb® antibody
discovery platform was used to sequence a complex mixture of
functional antibodies directly from the serum of a human patient
after receiving a COVID-19 vaccine.
It's a species-agnostic discovery platform
that specifically focuses on the biologically relevant antibodies
present in serum that directly confer immunity.
Titled "De Novo Protein Sequencing of Antibodies for
Identification of Neutralizing Antibodies in Human Plasma Post
SARS-CoV-2 Vaccination," the study highlights how de novo antibody
sequencing, a method that identifies antibodies directly from blood
samples without relying on genetic databases, provides valuable
information on unique and functional antibodies present in serum.
By leveraging de novo antibody sequencing, the study identified
antibodies that were not present in traditional B-cell sequencing
data, underscoring the significance of this innovative and
complementary approach.
"The integration of de novo sequencing with proteomics has
enabled us to uncover a broader range of antibodies, some of which
may play critical roles in immunity but are often overlooked in
conventional analyses," said Dr. Thierry Le
Bihan, Principal Scientist of Polyclonal Sequencing at Rapid
Novor. "De novo protein sequencing shows promise for thorough
antibody discovery, and further methodological developments are
anticipated to improve the field even more."
The study also revealed that monoclonal antibodies (mAbs)
derived from polyclonal antibodies (pAbs) retained strong
affinities, similar or even better than the original pAb with
potent neutralizing capabilities against SARS-CoV-2. These findings
open new avenues for developing highly specific and effective
therapeutics.
"The REpAb® workflow used in this study is ideally suited for
integration into any antibody and biotherapeutic discovery
pipeline," said Dr. Thierry Le
Bihan. "It's a species-agnostic discovery platform that
specifically focuses on the biologically relevant antibodies
present in serum that directly confer immunity."
With 100+ polyclonal antibody sequencing projects under their
belt and a 100% success rate, the team at Rapid Novor is actively
working with pharmaceutical companies and biotechnology partners to
integrate REpAb® into critical workflows for the discovery of
highly potent and developable antibodies.
The peer-reviewed paper is available in Nature Communications,
the link is provided here.
About Rapid Novor
Rapid Novor Inc., is the world's leader in antibody protein
sequencing technology. Specializing in the field of mass
spectrometry-based proteomics, the team has developed the
technology to directly sequence antibody proteins without needing
access to genomic information. Located at the Kitchener-Waterloo high-tech hub, the company
continues to build its technology portfolios based on years of
scientific research and inventions. The company's vision is to
elevate human health by decoding immunity. For information, please
visit http://www.rapidnovor.com. Follow @rapidnovor on X (formerly
Twitter) or LinkedIn.
Media Contact
Mingjie Xie, Rapid Novor Inc, 1
(855) 899-9990, pr@rapidnovor.com, rapidnovor.com
View original content to download
multimedia:https://www.prweb.com/releases/de-novo-antibody-protein-sequencing-reveals-novel-functional-and-neutralizing-antibodies-post-sars-cov-2-vaccination-302273435.html
SOURCE Rapid Novor Inc